Loading
Life sciences · Review
Asian Journal of Microbiology and Biotechnology · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Extended-spectrum β-lactamase (ESBL), AmpC β-lactamase and carbapenem resistance in Enterobacterales threaten the reliability of empirical therapy and the interpretation of routine antimicrobial-resistance surveillance in Sri Lanka. This critical narrative review evaluates the available human, molecular, environmental and policy evidence, with particular attention to whether studies genuinely establish temporal trends. Peer-reviewed research and relevant institutional documents published through 24 August 2026 were identified through scholarly-source searching, reference tracing and verification of bibliographic records. Sri Lankan studies document substantial ESBL production among selected urinary and hospital isolates, alongside clinically important plasmid-mediated AmpC enzymes and diverse carbapenemase mechanisms, including OXA-48-like and NDM variants. Nevertheless, the reported proportions cannot be arranged into a coherent national time series because sampling frames, specimen types, geographical coverage, organism composition, phenotypic definitions and confirmatory testing differ markedly. Some studies intentionally enrolled resistant isolates, whereas others assessed all isolates in a laboratory population. Molecular investigations offer stronger evidence for the presence of specific enzymes and mobile genetic contexts than for their population prevalence or direction of spread. Studies of cancer patients, hospital wastewater and animal-associated environments expose additional reservoirs and high-risk settings but do not independently prove intersectoral transmission. Diagnostic co-production, altered permeability and variable carbapenemase expression further complicate the equivalence of resistance phenotype and resistance mechanism. The most defensible interpretation is that clinically significant ESBL, AmpC and carbapenemase-mediated resistance is well documented in Sri Lanka, while the magnitude and direction of national change remain inadequately established. A harmonised, denominator-explicit surveillance framework, targeted molecular confirmation and prospectively linked clinical and One Health datasets are priorities for translating isolated findings into actionable trends.